Drug intelligence / Profile preview

QY-1-T

Development stage: Phase 1
Lead developer: Zhongke Qiyuan
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

QY-1-T is a TCR-T cell therapy targeting HBV for the treatment of HBV-associated advanced liver cancer. This cellular immunotherapy is being developed by Zhongke Qiyuan (Shenzhen) Biotechnology Co., Ltd. The therapy is designed to target HBV in patients with liver cancer, particularly those with Barcelona stage (BCLC) C-D who have limited treatment options and typically survive only 3-6 months after diagnosis. TCR-T therapy represents a new approach in cancer immunotherapy, where T cells are engineered with T-cell receptors that can recognize specific antigens.

Targets

Hepatitis B virus peptide-HLA class I complex

Beyond the preview

Go deeper on QY-1-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QY-1-T.

Explore the full profile